Myqorzo

(Aficamten)

Phase 2Small molecule

Myqorzo is a small molecule that works as a Cardiac Myosin Inhibitor.[2] It is being investigated across 1 indication, with its most advanced program in Phase 2.[1]

Myqorzo is one of 37 small molecule programs targeting Hypertrophic Cardiomyopathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Hypertrophic CardiomyopathyActive, not recruiting

Hypertrophic CardiomyopathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

50 competitors in Hypertrophic Cardiomyopathy

#DrugCompanyPhaseTrials

Aldactone

Pfizer

Approved

2 2

Adenocard

Astellas

Approved

1 3

Lexiscan

Astellas

Approved

1 4

Zebeta

Teva

Approved

1 5

Bayer Aspirin

Bayer

Approved

—6

Cardizem

BBausch Health Americas, Inc.

Approved

2 7

Camzyos

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

19 8

Calan

VVal Adams

Approved

1 9

Xarelto

WWim Janssens

Approved

—10

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Efficacy and Safety

NCT06081894

Q1 2030

Phase 2/3Recruiting

Hypertrophic Cardiomyopathy

NCT06412666

Clinical

Trials by Indication[1]

Efficacy and Safety3 trials

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM

Active, not recruiting·CCytokinetics·Phase 3·NCT06081894·500 enrolled

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

Completed·CCytokinetics·Phase 3·NCT05767346·175 enrolled

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

Completed·CCytokinetics·Phase 3·NCT05186818·282 enrolled

Hypertrophic Cardiomyopathy1 trial

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

Recruiting·CCytokinetics·Phase 2/3·NCT06412666·55 enrolled

Adult1 trial

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

Enrolling by invitation·CCytokinetics·Phase 2/3·NCT04848506·900 enrolled

Unspecified2 trials

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

Completed·CCorxel Pharmaceuticals·Phase 3·NCT06116968·40 enrolled

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

Completed·CCytokinetics·Phase 1·NCT05924815·44 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 19, 2025

MYQORZO

NDA NDA219083

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Aficamten. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aficamten compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aficamten. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA219083). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Myqorzo. U.S. Food & Drug Administration.
[6]
PubMed — 1 publication indexed for Aficamten. U.S. National Library of Medicine.
[7]
SEC EDGAR — Cytokinetics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cardiac Myosin Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCytokinetics

Patent Landscape[5]

Patent Cliff

Jan 18, 2039

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10836755Jan 18, 2039

12370179Jul 15, 2042

Key Publications[6]

Aficamten in Obstructive HCM: SEQUOIA-HCM Phase 3

N Engl J MedAug 31, 2024DOI: 10.1056/NEJMoa2408752

Myqorzo

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2030

Trials by Indication[1]

Efficacy and Safety3 trials

Hypertrophic Cardiomyopathy1 trial

Adult1 trial

Unspecified2 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Key Publications[6]

Related News